UPDATE: Medicines Co. (MDCO) Says Milano Study Interim Data Inconclusive - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 30, 2016 4:30 PM EDT)
Medicines Co. (NASDAQ: MDCO) said interim analysis of the first 40 patients completing treatment in its Milano-Pilot study didn't meet the pre-defined efficacy threshold to stop early, according to Bloomberg. The company had hoped the analysis would allow early termination of the study, but so far data is "inconclusive."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dynavax (DVAX) Announces Significant Subgroup Data from HEPLISAV-B Phase 3
- Sunrun (RUN) Reports Energy Storage Partnership with LG Chem
- Pieris Pharma (PIRS) Receives Milestone Related to GLP Toxicity Study Initiation
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!